The ReadoutRevisiting biotech’s VC boom & getting ripped with CRISPR By Damian Garde and Meghana Keshavan Oct. 16, 2017 Reprints Alex Hogan/STAT The Readout for October 16, 2017 About the Authors Reprints Damian Garde National Biotech Reporter Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast. [email protected] @damiangarde Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. [email protected] @megkesh
The Readout Meghana Keshavan Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
The Readout Damian Garde Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Pharmalot Ed Silverman and Damian Garde STAT Plus: Shortage of monkeys for early-stage research jeopardizes timelines for developing some drugs
Special Report Brittany Trang STAT Plus: As AI promises to revolutionize medical note-taking, concerns mount about accuracy and harm
A STAT Investigation Casey Ross and Bob Herman STAT Plus: Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need
